We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00382044
First Posted: September 28, 2006
Last Update Posted: May 23, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sir Charles Gairdner Hospital
  Purpose
The purpose of this study is to audit the effects of changing all hemodialysis patients from intravenous to subcutaneous administration of ESA's, to ensure that a cost-saving is achieved and that this does not occur at the expense of anemia control. The dose changes will occur according to usual clinical care of patients and not along a protocol.

Condition Intervention
Kidney Failure, Chronic Anemia Drug: Eprex; Neorecormon; Aranesp

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Audit of the Effect of Changing From IV to SC Administration of Erythropoiesis Stimulating Agents in Haemodialysis Patients - Real Life Clinical Experience

Resource links provided by NLM:


Further study details as provided by Sir Charles Gairdner Hospital:

Estimated Enrollment: 150
Study Start Date: September 2006
Study Completion Date: April 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • On haemodialysis at a Sir Charles Gairdner Hospital Unit
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00382044


Locations
Australia, Western Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009
Sponsors and Collaborators
Sir Charles Gairdner Hospital
Investigators
Study Director: Neil C Boudville, MBBS Sir Charles Gairdner Hospital
  More Information

Responsible Party: Dr Neil Boudville, Sir Charles Gairdner Hospital
ClinicalTrials.gov Identifier: NCT00382044     History of Changes
Other Study ID Numbers: NB-06-10
First Submitted: September 27, 2006
First Posted: September 28, 2006
Last Update Posted: May 23, 2008
Last Verified: May 2008

Keywords provided by Sir Charles Gairdner Hospital:
Kidney Failure, Chronic
Dialysis
Anemia
epoetin

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Darbepoetin alfa
Hematinics